Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07469475 · ClinicalTrials.gov registry record · Phase 1

Effect of a Daily Supplement on Plasma PAI-1 Levels

A Phase 1 study of Aging and Endothelial Dysfunction, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Phase 1
Development phase
35
Enrollment target
2
Study locations

NCT07469475: Recruiting Phase 1 study of Aging and Endothelial Dysfunction, sponsored by University of California, Los Angeles.

NCT07469475 is a Phase 1 study of Aging and Endothelial Dysfunction that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 35 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07469475, a Phase 1 study of Aging and Endothelial Dysfunction, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Phase 1
Development phase
35 participants
Enrollment target
2
Study locations

Study Summary

In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Under physiological stress either due to the development of a disease such as diabetes or simply from aging, the endothelial cells can be impacted and become dysfunctional, thereby impairing their ability to make NO and even promoting the development of blood clots. When such endothelial dysfunction occurs, it may be a precursor for the future development of cardiovascular (CV) disease like hypertension or coronary artery disease later on in life in these patients. Therefore, the ability to enhance the local production or availability of NO within such affected blood vessels in patients identified as prone to endothelial dysfunction could play a positive role in either preventing or delaying the onset of endothelial dysfunction and subsequent CV disease in such patients. RM is an oral supplement consisting of natural ingredients and the amino acid, L-citrulline. In laboratory experiments with cells from the inner lining of blood vessels, the four components of RM have been shown to increase the concentration of NO and decrease the levels of some aging markers. In our recently completed study (manuscript currently in review), 31 young men and women took the supplement for 14 days and had no serious side effects. The supplement caused the expected potentially beneficial dilation of the blood vessels and decrease in the levels of Plasminogen Activator Inhibitor-1 (PAI-1), whose levels correlate with aging and risk of cardiovascular disease. In this study, healthy participants will consume the supplement for a 6-week period to determine if PAI-1 levels continue to be suppressed and also examine whether the supplement has an effect on other blood markers whose levels can change

Primary Outcome

Blood levels of Plasminogen Activator Inhibitor-1 (PAI-1), a marker that correlates with aging and risk of cardiovascular disease, will be measured through a standard blood draw. Measurement units are ng/mL.

Interventions

  • DIETARY_SUPPLEMENT Supplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama

Study Locations (2)

California

  • UCLA - Los Angeles
  • UCLA The Men's Clinic - Santa Monica

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2026-02-24
Est. Completion 2026-12
Phase Phase 1

What NCT07469475 shows while recruiting

NCT07469475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 1 intervention - of which Supplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama is the first listed.

NCT07469475 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07469475 about?

NCT07469475 is a clinical study titled "Effect of a Daily Supplement on Plasma PAI-1 Levels". In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Unde...

What is the current status of trial NCT07469475?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2026-02-24. Estimated completion is 2026-12.

What conditions does trial NCT07469475 study?

This clinical trial studies the following conditions: Aging, Endothelial Dysfunction, Senescence.

What interventions are being tested in trial NCT07469475?

The interventions under investigation include: Supplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07469475?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07469475 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07469475's enrollment target sits among peer trials

35 183rd of 262 higher than 80 of 262 other Aging trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07469475, the US trial registry maintained by the National Library of Medicine. NCT07469475 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.